Supernus Pharmaceuticals Inc (NASDAQ:SUPN) — Market Cap & Net Worth

$2.74 Billion USD · Rank #5206

Market Cap & Net Worth: Supernus Pharmaceuticals Inc (SUPN)

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) has a market capitalization of $2.74 Billion ($2.74 Billion) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5206 globally and #1648 in its home market, demonstrating a -5.04% decrease in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Supernus Pharmaceuticals Inc's stock price $47.85 by its total outstanding shares 57339350 (57.34 Million). Analyse Supernus Pharmaceuticals Inc operating cash flow efficiency to see how efficiently the company converts income to cash.

Supernus Pharmaceuticals Inc Market Cap History: 2015 to 2026

Supernus Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows growth from $770.64 Million to $2.74 Billion (10.09% CAGR).

Index Memberships

Supernus Pharmaceuticals Inc is a constituent of 4 market indices:

Index	Total Market Cap	Weight (%)	Rank by Market Cap
NASDAQ Health Care IXHC	$2.41 Trillion	0.11%	#126 of 976
NASDAQ Composite IXIC	$38.77 Trillion	0.01%	#566 of 3165
NASDAQ Biotechnology NBI	$1.67 Trillion	0.16%	#80 of 263
S&P Small-Cap 600 Index SML	$1.54 Trillion	0.15%	#224 of 602

Weight: Supernus Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.

Supernus Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Supernus Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.

Latest Price to Sales (P/S) Ratio

3.13x

Supernus Pharmaceuticals Inc's market cap is 3.13 times its annual revenue

Industry average: 0.87x Higher than industry average

Latest Price to Earnings (P/E) Ratio

28.07x

Supernus Pharmaceuticals Inc's market cap is 28.07 times its annual earnings

Industry average: 4.18x Higher than industry average

What These Ratios Tell Investors:

Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
Industry comparison provides context for whether the company is valued higher or lower than peers.

Year	Market Cap (USD)	Revenue (USD)	Net Income (USD)	P/S Ratio	P/E Ratio
2015	$770.64 Million	$144.43 Million	$14.02 Million	5.34x	54.98x
2016	$1.45 Billion	$215.00 Million	$91.22 Million	6.73x	15.87x
2017	$2.28 Billion	$302.24 Million	$57.28 Million	7.56x	39.89x
2018	$1.90 Billion	$408.90 Million	$110.99 Million	4.66x	17.16x
2019	$1.36 Billion	$392.75 Million	$113.06 Million	3.46x	12.03x
2020	$1.44 Billion	$520.40 Million	$126.95 Million	2.77x	11.36x
2021	$1.67 Billion	$579.77 Million	$53.42 Million	2.88x	31.30x
2022	$2.05 Billion	$667.24 Million	$60.71 Million	3.07x	33.69x
2023	$1.66 Billion	$607.52 Million	$1.32 Million	2.73x	1260.94x
2024	$2.07 Billion	$661.82 Million	$73.86 Million	3.13x	28.07x

Competitor Companies of SUPN by Market Capitalization

Companies near Supernus Pharmaceuticals Inc in the global market cap rankings as of May 2, 2026.

Key companies related to Supernus Pharmaceuticals Inc by market ranking:

Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.

Market capitalization comparison (in billions USD)

Rank	Company	Symbol	Market Cap	Price
#499	Takeda Pharmaceutical Co Ltd ADR	NYSE:TAK	$52.60 Billion	$16.65
#525	Zoetis Inc	NYSE:ZTS	$50.31 Billion	$114.16
#526	Jiangsu Hengrui Medicine Co Ltd	SHG:600276	$50.29 Billion	CN¥53.88
#572	GALDERMA GROUP AG	NYSE:GALDY	$45.88 Billion	$42.09

Supernus Pharmaceuticals Inc Historical Marketcap From 2015 to 2026

Between 2015 and today, Supernus Pharmaceuticals Inc's market cap moved from $770.64 Million to $ 2.74 Billion, with a yearly change of 10.09%.

Year	Market Cap	Change (%)
2026	$2.74 Billion	-3.72%
2025	$2.85 Billion	+37.44%
2024	$2.07 Billion	+24.95%
2023	$1.66 Billion	-18.87%
2022	$2.05 Billion	+22.33%
2021	$1.67 Billion	+15.90%
2020	$1.44 Billion	+6.07%
2019	$1.36 Billion	-28.60%
2018	$1.90 Billion	-16.64%
2017	$2.28 Billion	+57.82%
2016	$1.45 Billion	+87.87%
2015	$770.64 Million	--

End of Day Market Cap According to Different Sources

On May 2nd, 2026 the market cap of Supernus Pharmaceuticals Inc was reported to be:

Source	Market Cap
Yahoo Finance	$2.74 Billion USD
MoneyControl	$2.74 Billion USD
MarketWatch	$2.74 Billion USD
marketcap.company	$2.74 Billion USD
Reuters	$2.74 Billion USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About Supernus Pharmaceuticals Inc

NASDAQ:SUPN USA Drug Manufacturers - Specialty & Generic

Market Cap

$2.74 Billion

Market Cap Rank

#5206 Global

#1648 in USA

Share Price

$47.85

Change (1 day)

-0.31%

52-Week Range

$30.94 - $57.00

All Time High

$59.85